Global Blood Therapeutics, Inc. (GBT)
After hours:
Chart Events
Performance Outlook
| Previous Close | 27.73 |
| Open | 27.37 |
| Bid | 27.30 x 1200 |
| Ask | 29.55 x 1000 |
| Day's Range | 27.14 - 29.13 |
| 52 Week Range | 24.61 - 52.49 |
| Volume | |
| Avg. Volume | 1,554,007 |
| Market Cap | 1.868B |
| Beta (5Y Monthly) | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.45 |
| Earnings Date | Feb 22, 2022 - Feb 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 69.05 |
Fair Value
Related Research
- Global Blood Therapeutics, Inc.Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features our annual pharmaceutical pipeline, a fresh look at Barry Callebaut's chocolate operation, the buzz around RingCentral, and SAP, Subsea 7, and Just Eat Takeaway.RatingFair ValueEconomic Moat3 days agoMorningstar
- GlobeNewswire
Oxbryta® (voxelotor) Tablets for Oral Suspension, A New Dispersible Tablet Dosage Form, Now Available for Patients with Sickle Cell Disease in the United States
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced Oxbryta® (voxelotor) tablets for oral suspension, a new dispersible, once-daily tablet dosage form recently approved by the U.S. Food and Drug Administration (FDA), is now available through GBT’s specialty pharmacy partner network in the United States. On December 17, 2021, the FDA approved Oxbryta (voxelotor) tablets for the treatment of sickle cell disease (SCD) in
- TipRanks
Oppenheimer Bullish on These 2 Stocks for 70% Upside (Or More)
The holidays are behind us, the New Year is getting into full swing, and that means it’s time to figure out, if we can, just where we’re headed in 2022. Last year saw strong gains in the stock markets; the S&P 500 grew 29%, far above the 7% to 8% annual average. The big question for investors is, will the markets keep up this blistering pace? The general consensus is, it won’t – although that doesn’t mean we’re in for a bad year. John Stoltzfus, chief investment strategist with Oppenheimer, note
- GlobeNewswire
GBT Announces New Employment Inducement Grants
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on January 1, 2022, the compensation committee of GBT’s board of directors granted 10 new employees options to purchase an aggregate of 15,225 shares of the company’s common stock with a per share exercise price of $29.27 and restricted stock units for an aggregate of 41,830 shares of the company’s common stock. These awards were made under GBT’s Amended and Res
